Adalvo announces the successful completion of the Pivotal BE study for Azacitidine 300mg film-coated tablets in adult patients with acute myeloid leukaemia (AML).
Following the successful EU Pivotal BE study, Azacitidine is now dossier-ready and Adalvo is preparing for DCP submission.
Based on the reference brand Onureg, Azacitidine recorded approximately $675 million in global sales in 2023, according to IQVIA.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!